Skip to content
value.today
Innate Pharma, SA logo

Innate Pharma, SA

Total raised
$27 M
1 round on record
Latest round
$27 M
Nov 2013
First round on record
Nov 2013
Today
Went public
See the company page

Innate Pharma, SA is listed today as Innate Pharma SA: market value, financials and filings are on its company page.

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Innate Pharma, SA
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2013$27 MNo. 1$10 to $50 million

Innate Pharma, SA: Raise no. 1, Nov 2013

Investors in this round

6 investors had bought by the notice of Jan 31, 2014: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$27 M of $27 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
$5 million to $25 million
Sales commissions
$1,635,251
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Limited Liability Company, incorporated in France

People named in the notice

  • Herve BRAILLY · Executive Officer · Chairman of Executive Board and CEO

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Leerink Swann LLC (CRD 39011) · New York, New YorkSold in CA, NY, and outside the US

Signed by Herve BRAILLY, Chairman of Exec Board and CEO. Source: SEC Form D, newest notice filed Jan 31, 2014. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Innate Pharma, SA had revenue between $5 million and $25 million when it filed its newest notice of a funding round (Jan 2014).

    SEC Form D (revenue range) · Jan 2014

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Jan 2014

Products and services#

No products or services of Innate Pharma, SA are on record.

Investors#

No investor of Innate Pharma, SA is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 6 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Innate Pharma, SA
NameRoleNamed in
Herve BRAILLYChairman of Executive Board and CEOJan 2014

Went public since 2019. Its SEC number is that of a company listed on a stock exchange.